272 related articles for article (PubMed ID: 34103405)
1. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift).
Cohen SB; Pope J; Haraoui B; Mysler E; Diehl A; Lukic T; Liu S; Stockert L; Germino R; Menon S; Shi H; Keystone EC
RMD Open; 2021 Jun; 7(2):. PubMed ID: 34103405
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.
Cohen SB; Pope J; Haraoui B; Irazoque-Palazuelos F; Korkosz M; Diehl A; Rivas JL; Lukic T; Liu S; Stockert L; Iikuni N; Keystone EC
Lancet Rheumatol; 2019 Sep; 1(1):e23-e34. PubMed ID: 38229356
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
Fleischmann R; Haraoui B; Buch MH; Gold D; Sawyerr G; Shi H; Diehl A; Lee K
Rheumatol Ther; 2023 Apr; 10(2):375-386. PubMed ID: 36534208
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
[TBL] [Abstract][Full Text] [Related]
5. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
[TBL] [Abstract][Full Text] [Related]
9. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P; Mease PJ; Fleishaker D; Wu J; Coates LC; Behrens F; Gladman DD; Kivitz AJ; Wei JC; Shirinsky I; Menon S; Romero AB; Fallon L; Hsu MA; Wang C; Kanik KS
Lancet Rheumatol; 2021 Jan; 3(1):e28-e39. PubMed ID: 38273637
[TBL] [Abstract][Full Text] [Related]
11. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Genovese MC; van Vollenhoven RF; Wilkinson B; Wang L; Zwillich SH; Gruben D; Biswas P; Riese R; Takiya L; Jones TV
Arthritis Res Ther; 2016 Jun; 18():145. PubMed ID: 27334658
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C; Burmester G; Nash P; Zerbini CA; Soma K; Kwok K; Hendrikx T; Bananis E; Fleischmann R
Ann Rheum Dis; 2016 Jul; 75(7):1293-301. PubMed ID: 26275429
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Strand V; van der Heijde D; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Clin Exp Rheumatol; 2020; 38(5):848-857. PubMed ID: 31858963
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
19. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Haraoui B; Khraishi M; Choquette D; Lisnevskaia L; Teo M; Kinch C; Galos C; Roy P; Gruben D; Woolcott JC; Vaillancourt J; Sampalis JS; Keystone EC;
Arthritis Care Res (Hoboken); 2023 Feb; 75(2):240-251. PubMed ID: 35678771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
